APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inflammatory Bowel Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Inflammatory Bowel Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchInflammatory Bowel Disease Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Inflammatory Bowel Disease Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inflammatory Bowel Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inflammatory Bowel Disease Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Inflammatory Bowel Disease Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Inflammatory Bowel Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Inflammatory Bowel Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Inflammatory Bowel Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inflammatory Bowel Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Inflammatory Bowel Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Inflammatory Bowel Disease Drugs include Takeda Pharmaceutical, Sanofi, Johnson and Johnson, Novartis AG, Mylan Pharmaceuticals, Roche, Pfizer, AbbVie Inc and UCB S.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Inflammatory Bowel Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Inflammatory Bowel Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Inflammatory Bowel Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inflammatory Bowel Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Inflammatory Bowel Disease Drugs Segment by Company

Takeda Pharmaceutical

Sanofi

Johnson and Johnson

Novartis AG

Mylan Pharmaceuticals

Roche

Pfizer

AbbVie Inc

UCB S.A.

Quest Medical

Merck & Co, Inc

Eli-Lilly

Celltrion Healthcare

Bristol Myers Squibb

Biocon Ltd

Abbott Laboratories

Inflammatory Bowel Disease Drugs Segment by Type

Biologics

Corticosteroids

Immunomodulators

Antibiotics

Amino-salicylates

Others

Inflammatory Bowel Disease Drugs Segment by Application

Indeterminate Colitis

Ulcerative Colitis

Crohns Disease

Others

Inflammatory Bowel Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inflammatory Bowel Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inflammatory Bowel Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inflammatory Bowel Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Inflammatory Bowel Disease Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Inflammatory Bowel Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Inflammatory Bowel Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Inflammatory Bowel Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Inflammatory Bowel Disease Drugs Industry Trends Table 2. Inflammatory Bowel Disease Drugs Industry Drivers Table 3. Inflammatory Bowel Disease Drugs Industry Opportunities and Challenges Table 4. Inflammatory Bowel Disease Drugs Industry Restraints Table 5. Global Inflammatory Bowel Disease Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Inflammatory Bowel Disease Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Inflammatory Bowel Disease Drugs Sales Market Share by Manufacturers Table 9. Global Inflammatory Bowel Disease Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Inflammatory Bowel Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Inflammatory Bowel Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Inflammatory Bowel Disease Drugs Manufacturers, Product Type & Application Table 13. Global Inflammatory Bowel Disease Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Inflammatory Bowel Disease Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Biologics Table 17. Major Manufacturers of Corticosteroids Table 18. Major Manufacturers of Immunomodulators Table 19. Major Manufacturers of Antibiotics Table 20. Major Manufacturers of Amino-salicylates Table 21. Major Manufacturers of Others Table 22. Global Inflammatory Bowel Disease Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Inflammatory Bowel Disease Drugs Sales by Type (2021-2026) & (k units) Table 24. Global Inflammatory Bowel Disease Drugs Sales by Type (2027-2032) & (k units) Table 25. Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2021-2026) Table 26. Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2027-2032) Table 27. Global Inflammatory Bowel Disease Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Inflammatory Bowel Disease Drugs Revenue by Type (2021-2026) & (k units) Table 29. Global Inflammatory Bowel Disease Drugs Revenue by Type (2027-2032) & (k units) Table 30. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Indeterminate Colitis Table 33. Major Manufacturers of Ulcerative Colitis Table 34. Major Manufacturers of Crohns Disease Table 35. Major Manufacturers of Others Table 36. Global Inflammatory Bowel Disease Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Inflammatory Bowel Disease Drugs Sales by Application (2021-2026) & (k units) Table 38. Global Inflammatory Bowel Disease Drugs Sales by Application (2027-2032) & (k units) Table 39. Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2021-2026) Table 40. Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2027-2032) Table 41. Global Inflammatory Bowel Disease Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Inflammatory Bowel Disease Drugs Revenue by Application (2021-2026) & (k units) Table 43. Global Inflammatory Bowel Disease Drugs Revenue by Application (2027-2032) & (k units) Table 44. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2021-2026) Table 45. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2027-2032) Table 46. Global Inflammatory Bowel Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Inflammatory Bowel Disease Drugs Sales by Region (2021-2026) & (k units) Table 48. Global Inflammatory Bowel Disease Drugs Sales Market Share by Region (2021-2026) Table 49. Global Inflammatory Bowel Disease Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Inflammatory Bowel Disease Drugs Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 53. North America Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 54. Europe Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 56. Europe Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 63. Global Inflammatory Bowel Disease Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Inflammatory Bowel Disease Drugs Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Inflammatory Bowel Disease Drugs Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Region (2021-2026) Table 67. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Region (2027-2032) Table 68. Takeda Pharmaceutical Company Information Table 69. Takeda Pharmaceutical Business Overview Table 70. Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Product Portfolio Table 72. Takeda Pharmaceutical Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Inflammatory Bowel Disease Drugs Product Portfolio Table 77. Sanofi Recent Development Table 78. Johnson and Johnson Company Information Table 79. Johnson and Johnson Business Overview Table 80. Johnson and Johnson Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Johnson and Johnson Inflammatory Bowel Disease Drugs Product Portfolio Table 82. Johnson and Johnson Recent Development Table 83. Novartis AG Company Information Table 84. Novartis AG Business Overview Table 85. Novartis AG Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis AG Inflammatory Bowel Disease Drugs Product Portfolio Table 87. Novartis AG Recent Development Table 88. Mylan Pharmaceuticals Company Information Table 89. Mylan Pharmaceuticals Business Overview Table 90. Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Product Portfolio Table 92. Mylan Pharmaceuticals Recent Development Table 93. Roche Company Information Table 94. Roche Business Overview Table 95. Roche Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Roche Inflammatory Bowel Disease Drugs Product Portfolio Table 97. Roche Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Pfizer Inflammatory Bowel Disease Drugs Product Portfolio Table 102. Pfizer Recent Development Table 103. AbbVie Inc Company Information Table 104. AbbVie Inc Business Overview Table 105. AbbVie Inc Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. AbbVie Inc Inflammatory Bowel Disease Drugs Product Portfolio Table 107. AbbVie Inc Recent Development Table 108. UCB S.A. Company Information Table 109. UCB S.A. Business Overview Table 110. UCB S.A. Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. UCB S.A. Inflammatory Bowel Disease Drugs Product Portfolio Table 112. UCB S.A. Recent Development Table 113. Quest Medical Company Information Table 114. Quest Medical Business Overview Table 115. Quest Medical Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Quest Medical Inflammatory Bowel Disease Drugs Product Portfolio Table 117. Quest Medical Recent Development Table 118. Merck & Co, Inc Company Information Table 119. Merck & Co, Inc Business Overview Table 120. Merck & Co, Inc Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Merck & Co, Inc Inflammatory Bowel Disease Drugs Product Portfolio Table 122. Merck & Co, Inc Recent Development Table 123. Eli-Lilly Company Information Table 124. Eli-Lilly Business Overview Table 125. Eli-Lilly Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Eli-Lilly Inflammatory Bowel Disease Drugs Product Portfolio Table 127. Eli-Lilly Recent Development Table 128. Celltrion Healthcare Company Information Table 129. Celltrion Healthcare Business Overview Table 130. Celltrion Healthcare Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Celltrion Healthcare Inflammatory Bowel Disease Drugs Product Portfolio Table 132. Celltrion Healthcare Recent Development Table 133. Bristol Myers Squibb Company Information Table 134. Bristol Myers Squibb Business Overview Table 135. Bristol Myers Squibb Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Bristol Myers Squibb Inflammatory Bowel Disease Drugs Product Portfolio Table 137. Bristol Myers Squibb Recent Development Table 138. Biocon Ltd Company Information Table 139. Biocon Ltd Business Overview Table 140. Biocon Ltd Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Biocon Ltd Inflammatory Bowel Disease Drugs Product Portfolio Table 142. Biocon Ltd Recent Development Table 143. Abbott Laboratories Company Information Table 144. Abbott Laboratories Business Overview Table 145. Abbott Laboratories Inflammatory Bowel Disease Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Abbott Laboratories Inflammatory Bowel Disease Drugs Product Portfolio Table 147. Abbott Laboratories Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Inflammatory Bowel Disease Drugs Distributors List Table 151. Inflammatory Bowel Disease Drugs Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Inflammatory Bowel Disease Drugs Product Image Figure 2. Global Inflammatory Bowel Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inflammatory Bowel Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Inflammatory Bowel Disease Drugs Sales (2021-2032) & (k units) Figure 5. Global Inflammatory Bowel Disease Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Inflammatory Bowel Disease Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Biologics Image Figure 9. Corticosteroids Image Figure 10. Immunomodulators Image Figure 11. Antibiotics Image Figure 12. Amino-salicylates Image Figure 13. Others Image Figure 14. Global Inflammatory Bowel Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Inflammatory Bowel Disease Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Inflammatory Bowel Disease Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Inflammatory Bowel Disease Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2021-2032) Figure 20. Indeterminate Colitis Image Figure 21. Ulcerative Colitis Image Figure 22. Crohns Disease Image Figure 23. Others Image Figure 24. Global Inflammatory Bowel Disease Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Inflammatory Bowel Disease Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2021-2032) Figure 27. Global Inflammatory Bowel Disease Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Inflammatory Bowel Disease Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2021-2032) Figure 30. North America Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 32. U.S. Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 37. Germany Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 44. China Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 52. Brazil Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Inflammatory Bowel Disease Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Inflammatory Bowel Disease Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Inflammatory Bowel Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 63. North America Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Inflammatory Bowel Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Europe Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Inflammatory Bowel Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Inflammatory Bowel Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Inflammatory Bowel Disease Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Inflammatory Bowel Disease Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Corticosteroids
  • Immunomodulators
  • Antibiotics
  • Amino-salicylates
  • Others
Applications
  • Indeterminate Colitis
  • Ulcerative Colitis
  • Crohns Disease
  • Others
Companies covered
  • Takeda Pharmaceutical
  • Sanofi
  • Johnson and Johnson
  • Novartis AG
  • Mylan Pharmaceuticals
  • Roche
  • Pfizer
  • AbbVie Inc
  • UCB S.A.
  • Quest Medical
  • Merck & Co, Inc
  • Eli-Lilly
  • Celltrion Healthcare
  • Bristol Myers Squibb
  • Biocon Ltd
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Inflammatory Bowel Disease Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Inflammatory Bowel Disease Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Inflammatory Bowel Disease Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Inflammatory Bowel Disease Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Inflammatory Bowel Disease Drugs Market Dynamics
  1. 2.1 Inflammatory Bowel Disease Drugs Industry Trends
  2. 2.2 Inflammatory Bowel Disease Drugs Industry Drivers
  3. 2.3 Inflammatory Bowel Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Inflammatory Bowel Disease Drugs Industry Restraints
3 Inflammatory Bowel Disease Drugs Market by Manufacturers
  1. 3.1 Global Inflammatory Bowel Disease Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Inflammatory Bowel Disease Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Inflammatory Bowel Disease Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Inflammatory Bowel Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Inflammatory Bowel Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Inflammatory Bowel Disease Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Inflammatory Bowel Disease Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Inflammatory Bowel Disease Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Inflammatory Bowel Disease Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Inflammatory Bowel Disease Drugs Tier 1, Tier 2, and Tier 3
4 Inflammatory Bowel Disease Drugs Market by Type
  1. 4.1 Inflammatory Bowel Disease Drugs Type Introduction
  2. 4.1.1 Biologics
  3. 4.1.2 Corticosteroids
  4. 4.1.3 Immunomodulators
  5. 4.1.4 Antibiotics
  6. 4.1.5 Amino-salicylates
  7. 4.1.6 Others
  8. 4.2 Global Inflammatory Bowel Disease Drugs Sales by Type
  9. 4.2.1 Global Inflammatory Bowel Disease Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Inflammatory Bowel Disease Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Inflammatory Bowel Disease Drugs Revenue by Type
  13. 4.3.1 Global Inflammatory Bowel Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Inflammatory Bowel Disease Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2021-2032)
5 Inflammatory Bowel Disease Drugs Market by Application
  1. 5.1 Inflammatory Bowel Disease Drugs Application Introduction
  2. 5.1.1 Indeterminate Colitis
  3. 5.1.2 Ulcerative Colitis
  4. 5.1.3 Crohns Disease
  5. 5.1.4 Others
  6. 5.2 Global Inflammatory Bowel Disease Drugs Sales by Application
  7. 5.2.1 Global Inflammatory Bowel Disease Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Inflammatory Bowel Disease Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Inflammatory Bowel Disease Drugs Revenue by Application
  11. 5.3.1 Global Inflammatory Bowel Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Inflammatory Bowel Disease Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2021-2032)
6 Global Inflammatory Bowel Disease Drugs Sales by Region
  1. 6.1 Global Inflammatory Bowel Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Inflammatory Bowel Disease Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Inflammatory Bowel Disease Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Inflammatory Bowel Disease Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Inflammatory Bowel Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Inflammatory Bowel Disease Drugs Revenue by Region
  1. 7.1 Global Inflammatory Bowel Disease Drugs Revenue by Region
  2. 7.1.1 Global Inflammatory Bowel Disease Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Inflammatory Bowel Disease Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Inflammatory Bowel Disease Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Inflammatory Bowel Disease Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Inflammatory Bowel Disease Drugs Revenue (2021-2032)
  8. 7.2.2 North America Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Inflammatory Bowel Disease Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Inflammatory Bowel Disease Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Inflammatory Bowel Disease Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Inflammatory Bowel Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Inflammatory Bowel Disease Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson and Johnson
  14. 8.3.1 Johnson and Johnson Company Information
  15. 8.3.2 Johnson and Johnson Business Overview
  16. 8.3.3 Johnson and Johnson Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson and Johnson Inflammatory Bowel Disease Drugs Product Portfolio
  18. 8.3.5 Johnson and Johnson Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Inflammatory Bowel Disease Drugs Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Mylan Pharmaceuticals
  26. 8.5.1 Mylan Pharmaceuticals Company Information
  27. 8.5.2 Mylan Pharmaceuticals Business Overview
  28. 8.5.3 Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Product Portfolio
  30. 8.5.5 Mylan Pharmaceuticals Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Inflammatory Bowel Disease Drugs Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inflammatory Bowel Disease Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 AbbVie Inc
  44. 8.8.1 AbbVie Inc Company Information
  45. 8.8.2 AbbVie Inc Business Overview
  46. 8.8.3 AbbVie Inc Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Inc Inflammatory Bowel Disease Drugs Product Portfolio
  48. 8.8.5 AbbVie Inc Recent Developments
  49. 8.9 UCB S.A.
  50. 8.9.1 UCB S.A. Company Information
  51. 8.9.2 UCB S.A. Business Overview
  52. 8.9.3 UCB S.A. Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 UCB S.A. Inflammatory Bowel Disease Drugs Product Portfolio
  54. 8.9.5 UCB S.A. Recent Developments
  55. 8.10 Quest Medical
  56. 8.10.1 Quest Medical Company Information
  57. 8.10.2 Quest Medical Business Overview
  58. 8.10.3 Quest Medical Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Quest Medical Inflammatory Bowel Disease Drugs Product Portfolio
  60. 8.10.5 Quest Medical Recent Developments
  61. 8.11 Merck & Co, Inc
  62. 8.11.1 Merck & Co, Inc Company Information
  63. 8.11.2 Merck & Co, Inc Business Overview
  64. 8.11.3 Merck & Co, Inc Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck & Co, Inc Inflammatory Bowel Disease Drugs Product Portfolio
  66. 8.11.5 Merck & Co, Inc Recent Developments
  67. 8.12 Eli-Lilly
  68. 8.12.1 Eli-Lilly Company Information
  69. 8.12.2 Eli-Lilly Business Overview
  70. 8.12.3 Eli-Lilly Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eli-Lilly Inflammatory Bowel Disease Drugs Product Portfolio
  72. 8.12.5 Eli-Lilly Recent Developments
  73. 8.13 Celltrion Healthcare
  74. 8.13.1 Celltrion Healthcare Company Information
  75. 8.13.2 Celltrion Healthcare Business Overview
  76. 8.13.3 Celltrion Healthcare Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celltrion Healthcare Inflammatory Bowel Disease Drugs Product Portfolio
  78. 8.13.5 Celltrion Healthcare Recent Developments
  79. 8.14 Bristol Myers Squibb
  80. 8.14.1 Bristol Myers Squibb Company Information
  81. 8.14.2 Bristol Myers Squibb Business Overview
  82. 8.14.3 Bristol Myers Squibb Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bristol Myers Squibb Inflammatory Bowel Disease Drugs Product Portfolio
  84. 8.14.5 Bristol Myers Squibb Recent Developments
  85. 8.15 Biocon Ltd
  86. 8.15.1 Biocon Ltd Company Information
  87. 8.15.2 Biocon Ltd Business Overview
  88. 8.15.3 Biocon Ltd Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Biocon Ltd Inflammatory Bowel Disease Drugs Product Portfolio
  90. 8.15.5 Biocon Ltd Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories Inflammatory Bowel Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories Inflammatory Bowel Disease Drugs Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Inflammatory Bowel Disease Drugs Value Chain Analysis
  2. 9.1.1 Inflammatory Bowel Disease Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Inflammatory Bowel Disease Drugs Production Mode & Process
  6. 9.2 Inflammatory Bowel Disease Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Inflammatory Bowel Disease Drugs Distributors
  9. 9.2.3 Inflammatory Bowel Disease Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst